


Prognostic biomarker in COVID-19 patients



Medical Need

COVID-19 is a global health problem due to its high infection rate, the severity of the disease, the pressure on healthcare systems, its socioeconomic impact and the challenges in its control and prevention. Having a prognostic marker for the evolution of patients with COVID-19 is critical to effectively manage the disease, allocate resources efficiently and improve patient outcomes.

Oportunity

Prevalence

During 2019: 15% of COVID-19 patients developed 5% threatenina critical illness.

Market



The market for No COVID-19 diagnostic kits is prognostic estimated severe disease, grow at a CAGR linking life- of 8% over the deterioration period 2028.

Other solutios



other genetic to biomarkers clinical 2024- and death have been validated.

Tecnology

Non-invasive method to predict the clinical deterioration of patients with COVID-19, based on the study of the mRNA expression of a gene.

The sample is taken from nasopharyngeal exudate, which offers two advantages: it is non-invasive, and it improves sensitivity (the primary impact of the virus occurs in the upper respiratory tract).

The method allows results to be obtained quickly and affordably by RT-PCR, a technique widely used in the health sector.

Results

Two cohorts of patients were used:

- Discovery cohort (149 patients): Panel analysis of genes related to inflammatory and immune response. A single gene was obtained with differential expression in patients who were discharged vs. admitted to ICU/exitus.
- Validation cohort (168 patients): Analysis revealed a significant association (p<0.05).

Roadmap

IBIMA plataforma BIONAND is looking for a partner to further develop the technology through a codevelopment or licensing agreement.



Patent:

National patent application Priority: 12/15/2023



Translational Research Group in Cancer and other Prevalent Chronic Diseases

Contact:

Unidad de Innovación y Transferencia de Tecnología de IBIMA Plataforma BIONAND 🧖 transferencia@ibima.eu 952 36 76 00 @ www.ibima.eu





